Document is current
Any future updates will be listed below
-
Authors
Hidaka, Kaori
Goto-Yamaguchi, Lisa
Sueta, Aiko
Tomiguchi, Mai
Yamamoto, Yutaka
-
Funding
Funding for this research was provided by:
Ministry of Education, Culture, Sports, Science and Technology of Japan (23K14571)
AstraZeneca
Daiichi-Sankyo
Chugai Pharmaceutical
Gilead Science
Ono Pharmaceutical
Novartis Pharmaceuticals
Kumamoto University
- License Information
-
More Information
Article History
Received: 4 February 2025
Accepted: 22 March 2025
First Online: 9 April 2025
Declarations
:
: Author YY received research funding from AstraZeneca, Gilead Sciences, and Ono Pharmaceutical, and received honoraria from AstraZeneca, Chugai Pharmaceutical, Eli Lilly, Pfizer, Daiichi-Sankyo, and MSD. None of the other authors have any conflicts of interest.
: The study protocols were approved by the Institutional Review Board at Kumamoto University (approval no. 1016) in accordance with the Declaration of Helsinki.
: Informed consent was obtained from all individual patients included in the study.
